The recent development of propofol (DIPRIVAN).
Thompson
K A
KA
AstraZeneca, Wilmington DE 19850-5437, USA.
Goodale
D B
DB
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018686:Anesthetics, Intravenous / Q000009:adverse effects / Q000737:chemistry; D002614:Chelating Agents / Q000737:chemistry / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D003257:Consumer Product Safety; D017277:Drug Approval; D004340:Drug Contamination / Q000517:prevention & control; D004492:Edetic Acid / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D007239:Infections / Q000209:etiology; D007362:Intensive Care Units; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology; D011310:Preservatives, Pharmaceutical / Q000737:chemistry / Q000494:pharmacology; D015742:Propofol / Q000009:adverse effects / Q000737:chemistry; D014481:United States
D018686:Anesthetics, Intravenous; D002614:Chelating Agents; D011310:Preservatives, Pharmaceutical; D004492:Edetic Acid; D015742:Propofol